JP2008526695A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526695A5
JP2008526695A5 JP2007548720A JP2007548720A JP2008526695A5 JP 2008526695 A5 JP2008526695 A5 JP 2008526695A5 JP 2007548720 A JP2007548720 A JP 2007548720A JP 2007548720 A JP2007548720 A JP 2007548720A JP 2008526695 A5 JP2008526695 A5 JP 2008526695A5
Authority
JP
Japan
Prior art keywords
carbonyl
amino
naphthalene
acid
ylmethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007548720A
Other languages
English (en)
Japanese (ja)
Other versions
JP5123667B2 (ja
JP2008526695A (ja
Filing date
Publication date
Priority claimed from EP04031009A external-priority patent/EP1676834A1/en
Application filed filed Critical
Publication of JP2008526695A publication Critical patent/JP2008526695A/ja
Publication of JP2008526695A5 publication Critical patent/JP2008526695A5/ja
Application granted granted Critical
Publication of JP5123667B2 publication Critical patent/JP5123667B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007548720A 2004-12-30 2005-12-17 炎症の治療においてcxcr2阻害剤として使用される縮合二環式カルボキサミド誘導体 Expired - Fee Related JP5123667B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04031009.6 2004-12-30
EP04031009A EP1676834A1 (en) 2004-12-30 2004-12-30 Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
PCT/EP2005/013624 WO2006069656A1 (en) 2004-12-30 2005-12-17 Fused bicyclic carboxamide derivatives for use as cxcr2 inhibitors in the treatment of inflammation

Publications (3)

Publication Number Publication Date
JP2008526695A JP2008526695A (ja) 2008-07-24
JP2008526695A5 true JP2008526695A5 (cg-RX-API-DMAC10.html) 2009-02-12
JP5123667B2 JP5123667B2 (ja) 2013-01-23

Family

ID=34928051

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007548720A Expired - Fee Related JP5123667B2 (ja) 2004-12-30 2005-12-17 炎症の治療においてcxcr2阻害剤として使用される縮合二環式カルボキサミド誘導体

Country Status (21)

Country Link
US (2) US7919628B2 (cg-RX-API-DMAC10.html)
EP (2) EP1676834A1 (cg-RX-API-DMAC10.html)
JP (1) JP5123667B2 (cg-RX-API-DMAC10.html)
KR (1) KR20070091634A (cg-RX-API-DMAC10.html)
CN (1) CN101094830A (cg-RX-API-DMAC10.html)
AR (1) AR055830A1 (cg-RX-API-DMAC10.html)
AT (1) ATE543795T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005321609B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0519452A2 (cg-RX-API-DMAC10.html)
CA (1) CA2592430A1 (cg-RX-API-DMAC10.html)
IL (1) IL184173A (cg-RX-API-DMAC10.html)
MA (1) MA29113B1 (cg-RX-API-DMAC10.html)
MX (1) MX2007007068A (cg-RX-API-DMAC10.html)
NO (1) NO20073932L (cg-RX-API-DMAC10.html)
NZ (1) NZ556192A (cg-RX-API-DMAC10.html)
PE (1) PE20060855A1 (cg-RX-API-DMAC10.html)
RU (1) RU2404962C2 (cg-RX-API-DMAC10.html)
TW (1) TW200639141A (cg-RX-API-DMAC10.html)
UY (1) UY29322A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006069656A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200704089B (cg-RX-API-DMAC10.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
CN102351791B (zh) 2006-01-27 2014-10-29 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
MX2008015768A (es) 2006-06-28 2009-01-07 Sanofi Aventis Nuevos inhibidores de cxcr2.
JP5232144B2 (ja) 2006-06-28 2013-07-10 サノフイ Cxcr2阻害剤
JP5352454B2 (ja) * 2006-06-28 2013-11-27 サノフイ Cxcr2アンンタゴニスト
JP5352455B2 (ja) * 2006-06-30 2013-11-27 サノフイ Cxcr2阻害剤
CN101573359A (zh) * 2006-11-23 2009-11-04 诺瓦提斯公司 作为cxcr2拮抗剂的5-硫基甲基-吡唑并[1,5-a]嘧啶-7-醇衍生物
CA2670202A1 (en) * 2006-11-23 2008-05-29 Novartis Ag 5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists
CN102702082B (zh) * 2006-11-30 2014-12-17 陶氏益农公司 2-取代的-5-((1-烷硫基)烷基)吡啶的制备方法
WO2008151211A1 (en) * 2007-06-05 2008-12-11 Sanofi-Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
AU2013203591B2 (en) * 2009-05-01 2017-01-19 University Court Of The University Of Dundee Treatment or prophylaxis of proliferative conditions
WO2012079154A1 (en) * 2010-12-14 2012-06-21 Dalhousie University Selective estrogen receptor modulators
JP6215924B2 (ja) * 2012-06-19 2017-10-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規の二環式チオフェニルアミド化合物
EP2895481B1 (en) * 2012-09-12 2019-12-11 F.Hoffmann-La Roche Ag Non-annulated thiophenylamides as inhibitors of fatty acid binding protein (fabp) 4 and/or 5
WO2014114603A1 (en) * 2013-01-24 2014-07-31 F. Hoffmann-La Roche Ag Substituted thiazole compounds
SG10202009266PA (en) 2013-01-24 2020-10-29 Fibrogen Inc Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
CA2977839C (en) * 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
PL3925607T5 (pl) * 2014-04-15 2026-06-01 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
KR20170036753A (ko) * 2014-07-31 2017-04-03 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화학요법 유도된 말초 신경병증 (cipn)의 예방 및/또는 치료를 위한 cxcr2 길항제의 용도
CN105906608B (zh) * 2016-05-03 2018-10-19 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物
CN106187974B (zh) * 2016-07-01 2018-01-12 广州军区广州总医院 具有抗肿瘤作用的鱼藤素断环结构与氨基酸衍生物的合成方法
PL3717646T3 (pl) 2017-12-01 2025-10-27 The Texas A&M University System Leczenie antysensowe zespołu angelmana
KR20200118827A (ko) 2018-02-02 2020-10-16 마베릭스 온콜로지, 잉크. 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
GB201807924D0 (en) * 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
MX2021000293A (es) 2018-07-09 2021-07-15 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos antihelminticos.
KR20220002890A (ko) 2019-03-19 2022-01-07 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 아자-벤조티오펜 및 아자-벤조푸란 화합물
MX2022005810A (es) 2019-11-12 2022-06-08 Genzyme Corp Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente.
WO2021113808A1 (en) * 2019-12-05 2021-06-10 Genzyme Corporation Cftr-modulating arylamides
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds
BR112022024156A2 (pt) 2020-05-29 2023-02-14 Boehringer Ingelheim Animal Health Usa Inc Compostos heterocílicos antelmínticos
CN111559991B (zh) * 2020-06-01 2022-01-25 河南省锐达医药科技有限公司 一种萘胺类化合物及其盐的制备方法和应用
WO2023073641A1 (en) 2021-11-01 2023-05-04 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds
CN115385865B (zh) * 2022-06-29 2023-06-16 深圳大学 一种具有cxcr2抑制活性的小分子抑制剂及其制备方法与应用
CN116041300B (zh) * 2023-02-20 2024-04-26 沈阳药科大学 一种2,2-二甲基苯并吡喃类衍生物及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962224A (en) * 1987-12-23 1990-10-09 American Home Products Corporation N-naphthoylglycines as aldose reductase inhibitors
US4994477A (en) * 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
US6531467B2 (en) * 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
IT1317826B1 (it) 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
US6673791B2 (en) * 2001-07-30 2004-01-06 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors
GB2389580A (en) * 2002-06-12 2003-12-17 Bayer Ag 2-Naphthamide PGI2 antagonists
CN103145616B (zh) * 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US7544699B2 (en) * 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
EP1670804A2 (en) 2003-09-10 2006-06-21 GPC Biotech AG Heterobicyclic compounds as pharmaceutically active agents
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2005051940A2 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2006040646A1 (en) 2004-10-14 2006-04-20 Pfizer, Inc. Benzimidazole or indole amides as inhibitors of pin1
WO2006052722A1 (en) 2004-11-09 2006-05-18 Smithkline Beecham Corporation Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
AR055319A1 (es) 2005-03-17 2007-08-15 Wyeth Corp Derivados de isoquinoleina, composiciones farmaceuticas y usos

Similar Documents

Publication Publication Date Title
RU2007128949A (ru) Конденсированные бициклические карбоксамидные производные, используемые в качестве ингибиторов схсr2 для лечения воспалений
CA2558585C (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP5225076B2 (ja) チアゾール環を含むカルボン酸誘導体の医薬用途
RU2460525C2 (ru) Производные индола и индазола, обладающие консервирующим действием по отношению к клеткам, тканям и органам
RU2529860C2 (ru) Производное n-ацилантраниловой кислоты или его соль
JP6224771B2 (ja) オキサジアゾール・ジアリール化合物
JP2010513283A5 (cg-RX-API-DMAC10.html)
EP2193125A2 (en) Oxadiazole derivatives
JP2012529535A5 (cg-RX-API-DMAC10.html)
AU2010299114A1 (en) Substituted amide compound
WO2016148145A1 (ja) ピラゾロ[1,5-a]ピリミジン化合物
CA2126972C (en) Styrene derivative and salts thereof
HRP20161702T1 (hr) Novi derivati pirazina
JP4939226B2 (ja) チアゾール環を含むカルボン酸誘導体およびその医薬用途
JP2005514432A5 (cg-RX-API-DMAC10.html)
EP2978750B1 (en) "synthesis of dabigatran"
JP2021102645A (ja) メプリンアルファ及びベータの新規な阻害剤
ES2245690T3 (es) Procedimiento para preparar arilacetilaminotiazoles.
JP2009541383A5 (cg-RX-API-DMAC10.html)
TH71855B (th) สารยับยั้งแคสเปสซึ่งมีวงแหวนไอโซซาโซลีน
TH73058A (th) สารยับยั้งแคสเปสซึ่งมีวงแหวนไอโซซาโซลีน
HK1143808A (en) Oxadiazole diaryl compounds